Ulcer

Lavior Partners with the ADA & Walmart to Bridge the Healthcare Disparities Gap and Deliver Affordable, Life-Changing Solutions for Those Living With Diabetes

Retrieved on: 
Tuesday, January 16, 2024
Diabetes, Entrepreneurship, Patient, African Americans, Health care, Dodonaea viscosa, Partnership, Amputation, BIPOC, Environment, Abrasion, FDA, American Diabetes Association, Ulcer, Health equity, Wound, Black, Lead, Pharmaceutical industry

MIAMI, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Lavior Pharma (Lavior), the exclusive company offering comprehensive over-the-counter diabetic wound and skin treatments, announces a partnership with the American Diabetes Association (ADA) to further its mission of providing life-changing solutions for those patients and communities most affected by diabetes. The ADA has endorsed Lavior's Diabetic Hydrogel Wound Dressing with its Better Choices for Life mark for their efficacy, evidence-based research and ability to manage associative complications of diabetes in the initial stages, saving thousands of lives annually. Lavior is dedicated to making its life saving products easily accessible and affordable to those most impacted by diabetes through retail stores nationwide, including Walmart. Working closely with local and state governments, Lavior is taking the lead in addressing this nationwide problem by bringing this issue to the forefront with reasonable solutions to reduce diabetic amputations, healthcare costs, and improve patients' lives.

Key Points: 
  • Lavior is dedicated to making its life saving products easily accessible and affordable to those most impacted by diabetes through retail stores nationwide, including Walmart.
  • "We aim to reduce diabetic amputations and bridge the gap to help heal stubborn wounds, leading to longer lifespans.
  • The ADA's Better Choices for Life program is designed to help consumers make better-informed choices about products related to diabetes care.
  • Lavior products are available in Walmart nationwide and on Walmart.com for less than $20 for a 30-day supply.

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Retrieved on: 
Tuesday, January 9, 2024
Biology, Fibrosis, Organovo, UC, SAN, Partnership, Tissue, IBD, Inflammatory bowel disease, Executive, Cirrhosis, Research and development, Disease, 3D, NASH, Colitis, Ulcerative colitis, FXR, Ulcer

The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.

Key Points: 
  • The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
  • “We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman.
  • Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025.
  • The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024
Human, Treatment, Chronic pain, Homeostasis, PLXDC2, Ulcer, Disease, UC, Doctor of Philosophy, ECCO, Pharmacokinetics, NLRX1, Abstract, UZ Leuven, Library, Congress, European, Effect, Inflammatory Bowel Diseases, Inflammation, Patient, Translation, Immunometabolism, Safety, Landos, NEXUS, Pharmaceutical industry

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, INN, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Pediatrics, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Methotrexate, TNF, Axial, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Frankincense

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24

Retrieved on: 
Thursday, January 4, 2024
Janus, Commercialization, OD, Drug development, Completeness, CMO, Hepatocyte growth factor, Master of Science, Novo Holdings A/S, Ear, MD, Neurotrophic factors, Nerve, Mass, Burns (surname), Mouth ulcer, Perforation, Ulcer, Series, Scar, MPH, Patient, NK, Medical imaging

Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.

Key Points: 
  • Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.
  • Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory, and anti-fibrotic, suggesting it could be an efficacious and safe option to treat many current unmet needs in diseases of the cornea.
  • Claris expects to complete enrollment in its late-stage multi-center, randomized, double-masked, vehicle-controlled, parallel-group study, with a data readout expected in 1H2024.
  • Additional indications of interest that are being actively pursued by Claris, supported by preclinical and clinical data, include limbal stem cell deficiency and pre-existing corneal scar.

Cinesteam® Uses Cinnamon to Manage Wound Malodors

Retrieved on: 
Wednesday, January 3, 2024
Research, Laboratory, Coffee, Patient, Nature, Caregiver, Leg, Ulcer, Spice, Business

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- One of the quiet struggles that many medical patients face is the need to manage unpleasant smells created by wounds. Referred to as "wound malodors," these disagreeable scents can be released by chronic wounds such as tumoral wounds, fungating wounds, pressure ulcers, and infected leg ulcers.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- One of the quiet struggles that many medical patients face is the need to manage unpleasant smells created by wounds.
  • Referred to as "wound malodors," these disagreeable scents can be released by chronic wounds such as tumoral wounds, fungating wounds, pressure ulcers, and infected leg ulcers.
  • This is a fast, effective, and unintrusive solution to managing wound malodor — and it's all possible due to the natural adsorbent power of cinnamon.
  • Wound malodor isn't new, and there are many ways to attempt to manage it.

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urea, Medical Subject Headings, Marketing, European Commission, INN, Stomach, Heartburn, Infection, Allergy, Bloating, ATC, Helicobacter pylori, International, European, Nausea, Language, Inflammation, Duodenum, Laboratory, Water, Mass spectrometry, Indigestion, Peptic ulcer disease, Gastritis, Medication, Enzyme, Select, Committee, Patient, Carbon, Ammonia, Diagnosis, Anatomy, Medicine, Ulcer, Nature, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Pediatrics, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Methotrexate, TNF, Axial, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Frankincense

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Contraindication, AZA, Axial spondyloarthritis, Rash, Tissue, ACR20, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Adolescence, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Nonsteroidal anti-inflammatory drug, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Select, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Child, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, TNF, INN, Immune system, Etanercept, Ulcerative colitis, Adolescence, Caregiver, PUVA, ATC, Joint, Crohn's disease, Psoriatic arthritis, Bleeding, International, Headache, Disease, Common, Ageing, Nose, Language, Arthritis, Inflammation, Hypersensitivity, Allergy, Disease-modifying antirheumatic drug, European Medicines Agency, Ulcer, Select, Anatomy, Methotrexate, IIA, DMARD, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised